Effect of sterilized human fecal extract on the sensitivity of Escherichia coli ATCC 25922 to enrofloxacin

Journal of Antibiotics

Volumn 65, Issue 4, 2012, Pages 179-184

  Ahn, Youngbeom ^a   Sung, Kidon ^a   Rafii, Fatemeh ^a   Cerniglia, Carl E ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

E. coli; enrofloxacin; fluoroquinolone; sterilized human fecal extract

Indexed keywords

ACETIC ACID; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; ENROFLOXACIN; GLUCOSE; RESERPINE; SATURATED FATTY ACID; SUCROSE; UNSATURATED FATTY ACID;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; CONTROLLED STUDY; ESCHERICHIA COLI; FECES; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STERILIZED FECAL EXTRACT;

ANTI-INFECTIVE AGENTS; CARBONYL CYANIDE M-CHLOROPHENYL HYDRAZONE; DNA, BACTERIAL; ESCHERICHIA COLI; FATTY ACIDS; FECES; FLUOROQUINOLONES; HUMANS; KINETICS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, PHASE-CONTRAST; POLYMERASE CHAIN REACTION; RESERPINE;

ANIMALIA; ESCHERICHIA COLI;

EID: 84860362263     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2012.1     Document Type: Article

References (43)

1. Cerniglia, C. E. & Kotarski, S. Evaluation of veterinary drug residues in food for their potential to affect human intestinal microflora. Regul. Toxicol. Pharmacol. 29, 238-261 (1999). (Pubitemid 29323781)
2. Cerniglia, C. E. & Kotarski, S. Approaches in the safety evaluations of veterinary antimicrobial agents in food to determine the effects on the human intestinal microflora. J. Vet. Pharmacol. Ther. 28, 3-20 (2005). (Pubitemid 40353790)
3. Cho, H. J. et al. Monitoring of fluoroquinolone residual levels in chicken eggs by microbiological assay and confirmation by liquid chromatography. Biomed. Chromatogr. 22, 92-99 (2008).
4. Reyes-Herrera, I. & Donoghue, D. J. Antibiotic residues distribute uniformly in broiler chicken breast muscle tissue. J. Food Prot. 71, 223-5 (2008).
5. Donoghue, D. J., Reyes-Herrera, I., Schneider, M. J. & Blore, P. J. The relationship between blood and muscle samples to monitor for residues of the antibiotic enrofloxacin in chickens. Poult. Sci. 90, 481-485 (2011).
6. Angulo, F. J., Nargund, V. N. & Chiller, T. C. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J. Vet. Med. Series B-Infect. Dis. Vet. Public Health 51, 374-379 (2004). (Pubitemid 39547739)
7. Carman,R.J.et al. Antibiotics in the human food chain: Establishing no effect levels of tetracycline, neomycin, and erythromycin using a chemostat model of the human colonic microflora. Regul. Toxicol. Pharmacol. 43, 168-180 (2005). (Pubitemid 41427809)
8. Perrin-Guyomard, A. et al. Impact of ciprofloxacin in the human-flora-Associated (HFA) rat model: Comparison with the HFA mouse model. Regul. Toxicol. Pharmacol. 45, 66-78 (2006).
9. Silley, P. Impact of antimicrobial residues on gut communities: Are the new regulations effective? J. Appl. Microbiol. 102, 1220-1226 (2007). (Pubitemid 46633432)
10. Finlay, B. B. et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium-induced colitis. Infect. Immun. 79, 1536-1545 (2011).
11. EMA. The European Agency for the Evaluation of Medicinal products. Enrofloxacin (modification for bovine, porcine and poultry). EMEA/MRL/388/98-Final. Available at: /www.ema.europa.eu/pdfs/vet/mrls/038898en. pdfS (1998).
12. Joint FAO/WHO Expert Committee on Food Additives (JECFA). Evaluation of Certain Veterinary Drug Residues in Food: Forty-eight Meeting of the Joint FAO/WHO Expert Committee on Food Additives. WHO technical Report Series No. 39.: Geneva, Switzerland (1997).
13. Willmott, C. J. R. & Maxwell, A. A single point mutation in the DNA gyrase-A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex. Antimicrob. Agents Chemother. 37, 126-127 (1993). (Pubitemid 23019183)
14. Vila, J. et al. Association between double mutation in gyrA gene of ciprofloxacinresistant clinical isolates of Escherichiacoli and MICs. Antimicrob. Agents Chemother. 38, 2477-2479 (1994). (Pubitemid 24304253)
15. Ouabdesselam, S., Hooper, D. C., Tankovic, J. & Soussy, C. J. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichiacoli by singlestrand conformational polymorphism analysis and determination of levels of resistance conferred by 2 different single gyrA mutations. Antimicrob. Agents Chemother. 39, 1667-1670 (1995).
16. Everett, M. J., Jin, Y. F., Ricci, V. & Piddock, L. J. V. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40, 2380-2386 (1996). (Pubitemid 26328050)
17. Miyamae, S., Nikaido, H., Tanaka, Y. & Yoshimura, F. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42, 2119-2121 (1998). (Pubitemid 28363105)
18. Oethinger, M., Kern, W. V., Jellen-Ritter, A. S., McMurry, L. M. & Levy, S. B. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob. Agents Chemother. 44, 10-13 (2000). (Pubitemid 30010664)
19. Piddock, L. J. V., White, D. G., Gensberg, K., Pumbwe, L. & Griggs, D. J. Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44, 3118-3121 (2000).
20. Coldham, N. G., Webber, M., Woodward, M. J. & Piddock, L. J. V. A 96-well plate fluorescence assay for assessment of cellular permeability and active efflux in Salmonella enterica serovar Typhimurium and Escherichia coli. J. Antimicrob. Chemother. 65, 1655-1663 (2010).
21. Stephen, A. M. & Cummings, J. H. The microbial contribution to human faecal mass. J. Med. Microbiol. 13, 45-56 (1980). (Pubitemid 10164061)
22. Wagman, G. H., Bailey, J. V. & Weinstein, M. J. Binding of aminoglycosides to feces. Antimicrob. Agents Chemother. 6, 415-7 (1974).
23. Hazenberg, M. P., Pennock-Schroder, A. M., Van den Boom, M. & Van de Merwe, J. P. Binding to and antibacterial effect of ampicillin, neomycin and polymyxin B on human feces. J. Hyg. Camb 93, 27-34 (1984). (Pubitemid 14030332)
24. Veringa, E. M. & van der Waaij, D. Biological inactivation by feces of antimicrobial drugs applicable in selective decontamination of the digestive tract. J. Antimicrob. Chemother. 14, 605-612 (1984). (Pubitemid 15114506)
25. De Vries-Hospers, H., Jansen, G., Tonk, R., Oenema, D. & van der Waaij, D. The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance. Infection 21, 127-130 (1993). (Pubitemid 23112604)
26. Van Saene, J. J. M., van Saene, H. K. F. & Lerk, C. F. Inactivation of quinolones. J Infect. Dis 153, 999-1000 (1986).
27. Costons, G.M.P.J., Bos, L. P., Engels, L.G.J.B. & Janson, P. C. W. A new method for chemical analysis of faeces. Clinica Chimica Acta 150, 197-203 (1985). (Pubitemid 15016672)
28. Pasquali, F. & Manfreda, G. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella typhimurium and Pseudomonas aeruginosa. Vet. Microbiol. 119, 304-310 (2007). (Pubitemid 46027447)
29. Eaves, D. J., Liebana, E., Woodward, M. J. & Piddock, L. J. V. Detection of gyrA mutations in quinolone-resistant Salmonella enterica by denaturing high-performance liquid chromatography. J. Clin. Microbiol. 40, 4121-4125 (2002). (Pubitemid 35285799)
30. Tamura, K., Dudley, J., Nei, M. & Kumar, S. MEGA4: Molecular evolutionary genetics analysis (MEGA) software version 4.0. Mol. Biol.Evol. 24, 1596-1599 (2007). (Pubitemid 47236692)
31. Chapman, J. S. & Georgopapadakou, N. H. Fluorometric assay for fleroxacin uptake by bacterial-cells. Antimicrob. Agents Chemother. 33, 27-29 (1989). (Pubitemid 19015760)
32. Rafii, F., Park, M. & Wynne, R. Evidence for active drug efflux in fluoroquinolone resistance in Clostridium hathewayi. Chemotherapy 51, 256-262 (2005). (Pubitemid 41207046)
33. Song, B., Palleroni, N. J., Kerkhof, L. J. & Häggblom, M. M. Characterization of halobenzoate-degrading, denitrifying Azoarcus and Thauera isolates and description of Thauera chlorobenzoica sp. nov. Int. J. Syst. Evol. Microbiol. 51, 589-602 (2001). (Pubitemid 32266701)
34. Kamberi, M. et al. Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin. Antimicrob. Agents Chemother. 43, 525-529 (1999). (Pubitemid 29109514)
35. Costongs, G.M.P.J., Bos, L. P., Engels, L.G.J.B. & Janson, P. C. W. A new method for chemical-Analysis of feces. Clin. Chim. Acta 150, 197-203 (1985).
36. Aristilde, L. & Sposito, G. Binding of ciprofloxacin by humic substances: A molecular dynamics study. Environ. Toxicol. Chem. 29, 90-98 (2010).
37. Hao, W- L. & Lee, Y- K. Microflora of the gastrointestinal tract: A review. Methods Mol. Biol. 268, 491-502 (2004).
38. Cook, T. M., Brown, K. G., Boyle, J. V. & Goss, W. A. Bactericidal action of nalidixic acid on Bacillus subtilis. J. Bacteriol. 92, 1510-1514 (1966).
39. Li, Q. X., Bi, X. M., Diao, Y. J. & Deng, X. M. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens. Am. J. Vet. Res. 68, 812-815 (2007).
40. Sinensky, M. Homeoviscous adaptation-A homeostatic process that regulates the viscosity of membrane lipids in. Escherichia coli. Proc. Natl Acad. Sci. USA 71, 522-525 (1974).
41. Russell, N. J. & Fukunaga, N. A comparison of thermal adaptation of membrane lipids in psychrophilic and thermophilic bacteria. FEMS Microbiol. Rev. 75, 171-182 (1990). (Pubitemid 20211793)
42. Mejỳa, R., Gomez-Eichelmann, M. C. & Fernandez, M. S. Membrane fluidity of Escherichia coli during heat-shock. Biochem. Biophys. Acta 1239, 195-200 (1995).
43. Catry, B. et al. Antimicrobial resistance patterns of Escherichia coli through the digestive tract of veal calves. Microb. Drug Resist. -Mechanisms Epidemiol. Disease 13, 147-150 (2007). (Pubitemid 47196049)